Form 4: Artiva Biotherapeutics Director Receives Stock Option Grant

Artiva Biotherapeutics, Inc. Director Daniel G. Baker was granted 13,750 stock options with an exercise price of $1.61, vesting by June 2026 or the 2026 annual stockholder meeting.

Summary

• Daniel G. Baker, a Director of Artiva Biotherapeutics, Inc. (ARTV), acquired 13,750 Director Stock Options.
• The transaction date for this acquisition was June 24, 2025.
• The exercise price for these options is $1.61 per share.
• The options are set to expire on June 23, 2035.
• The shares subject to the option will vest in full on the earlier of June 24, 2026, or the date of the Issuer's 2026 annual stockholder meeting.
• This transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following this transaction, Daniel G. Baker beneficially owns 13,750 Director Stock Options directly.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction (stock option grant) which is a standard part of director compensation, generally viewed as neutral to slightly positive as it aligns interests, but not indicative of significant new company developments.

Positives

• The grant of stock options to Director Daniel G. Baker aligns his financial interests with the long-term performance and shareholder value creation of Artiva Biotherapeutics.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged and transparent approach to insider transactions.

Negatives

• No explicit negative information is contained within this routine Form 4 filing.

Risks

• This Form 4 filing, which reports a routine insider transaction, does not contain specific risk factors for the company.

Future Outlook

The document indicates that the granted stock options will vest in full on the earlier of June 24, 2026, or the date of the Issuer's 2026 annual stockholder meeting, providing a future milestone for the director's equity compensation.

Industry Context

The grant of stock options to a director is a common and standard practice in the biotechnology and broader corporate sectors for executive and director compensation. It is designed to align the interests of the director with the long-term performance of the company and its shareholders, a widely adopted governance principle.

Comparison to Industry Standards

• The grant of stock options as a form of director compensation is a standard practice across publicly traded companies, particularly in the biotechnology sector, which often uses equity-based incentives to attract and retain talent.
• The vesting schedule, tied to a specific future date or the annual meeting, is also a common mechanism to ensure continued commitment and performance from board members.
• While specific comparable companies or projects are not detailed in this filing, the general structure of this compensation aligns with typical industry benchmarks for non-employee director equity grants.

Corporate Governance

Related Party Transactions

• The grant of stock options to Daniel G. Baker, a Director of Artiva Biotherapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the director's interests with shareholders, potentially leading to better long-term decision-making focused on increasing share value.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• The granted stock options will vest in full on the earlier of June 24, 2026, or the date of the Issuer's 2026 annual stockholder meeting.

Key Dates

Keywords

Artiva Biotherapeutics, ARTV, SEC Form 4, Stock Options, Director Compensation, Insider Transaction, Daniel Baker, Equity Grant, Rule 10b5-1